Q1 2018 EPS Estimates for Heska Corp (HSKA) Raised by Analyst
Heska Corp (NASDAQ:HSKA) – Equities research analysts at B. Riley lifted their Q1 2018 earnings per share estimates for shares of Heska in a report issued on Thursday. B. Riley analyst K. Anderson now forecasts that the medical research company will post earnings of $0.37 per share for the quarter, up from their previous estimate of $0.31. B. Riley currently has a “Neutral” rating and a $77.00 price target on the stock. B. Riley also issued estimates for Heska’s Q2 2018 earnings at $0.48 EPS, Q3 2018 earnings at $0.47 EPS, Q4 2018 earnings at $0.67 EPS, FY2018 earnings at $1.99 EPS and FY2019 earnings at $2.17 EPS.
Heska (NASDAQ:HSKA) last announced its quarterly earnings data on Wednesday, February 28th. The medical research company reported $0.63 EPS for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.07. The firm had revenue of $36.04 million during the quarter, compared to analyst estimates of $40.56 million. Heska had a return on equity of 16.23% and a net margin of 7.53%. The company’s revenue was down 8.8% on a year-over-year basis. During the same period last year, the company earned $0.46 earnings per share.
Shares of Heska (NASDAQ:HSKA) opened at $66.87 on Monday. The company has a market capitalization of $484.39, a PE ratio of 51.05, a P/E/G ratio of 1.73 and a beta of 0.82. Heska has a 12-month low of $56.59 and a 12-month high of $115.00.
Several institutional investors have recently bought and sold shares of HSKA. TimesSquare Capital Management LLC acquired a new position in shares of Heska during the 4th quarter worth about $23,831,000. Park West Asset Management LLC grew its position in shares of Heska by 293.3% during the 4th quarter. Park West Asset Management LLC now owns 347,646 shares of the medical research company’s stock worth $27,885,000 after buying an additional 259,256 shares during the period. Redmile Group LLC acquired a new position in shares of Heska during the 4th quarter worth about $15,753,000. Atlantic Trust Group LLC acquired a new position in shares of Heska during the 3rd quarter worth about $16,059,000. Finally, Neuberger Berman Group LLC grew its position in shares of Heska by 34.2% during the 3rd quarter. Neuberger Berman Group LLC now owns 603,469 shares of the medical research company’s stock worth $53,160,000 after buying an additional 153,895 shares during the period. Institutional investors own 78.71% of the company’s stock.
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.